Tactile Medical reported fourth quarter (Q4) 2025 revenue of USD 103.6 million, up 21%. Q4 2025 gross margin was 78%, and net income reached USD 10.6 million. Adjusted EBITDA for the quarter was USD 22.9 million. For the full year (FY) 2025, total revenue was USD 329.5 million and adjusted EBITDA was USD 44.8 million. The company highlighted the publication of clinical data comparing Flexitouch Plus to usual care and reported serving over 95,000 patients with lymphedema and chronic inflammatory lung disease in 2025. For full year 2026, Tactile Medical expects revenue between USD 357 million and USD 365 million and adjusted EBITDA between USD 49 million and USD 51 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tactile Systems Technology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-016370), on February 17, 2026, and is solely responsible for the information contained therein.